GenVec shareholders might vote against imminent acquisition
Gene therapy research firm GenVec has been served with a class action lawsuit in Delaware by shareholders who oppose the company’s acquisition by Intrexon, citing a lack of advantages and an inaccurate SEC registration statement.
By Cara Salvatore (March 29, 2017, 6:23 PM EDT) -- Gene therapy research company GenVec Inc. was hit by a putative class action Tuesday in Delaware federal court by shareholders who say the company's imminent acquisition by Intrexon Corp. gives them a raw deal and that the merger registration statement is inaccurate....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

Access to case data within articles (numbers, filings, courts, nature of suit, and more.)

Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.

Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS